Multiple Myeloma in Relapsed and Refractory Disease
Research activity includes treatment approaches for relapsed multiple myeloma and relapsed/refractory multiple myeloma, with attention to disease control after prior therapy and options for patients with limited remaining treatment pathways.
- Relapsed multiple myeloma
- Relapsed/refractory multiple myeloma
- Disease recurrence
The trial portfolio reflects a focus on therapeutic strategies for patients requiring additional lines of myeloma treatment in the setting of prior treatment exposure.
Newly Diagnosed Multiple Myeloma in Older and Transplant-Ineligible Patients
Clinical research also addresses newly diagnosed multiple myeloma in patients aged 65 years and older, including those not eligible for autologous stem cell transplantation. This area centers on first-line treatment choices for patients who need non-transplant-based management.
- Newly diagnosed multiple myeloma
- Transplant-ineligible patients
- Older adults
Interest in this setting includes treatment selection for older patients and those with clinical factors that preclude ASCT.
Combination Therapy in Myeloma Treatment
The sponsor supports studies examining combination regimens built around established myeloma therapies, including lenalidomide, dexamethasone, carfilzomib, and daratumumab. These efforts are directed toward improving disease response in both newly diagnosed and relapsed settings.
- Lenalidomide-based therapy
- Carfilzomib combinations
- Daratumumab-based treatment
Research in this domain spans treatment intensification and regimen selection across different stages of multiple myeloma.
Minimal Residual Disease and Disease Control
One area of interest is the assessment of minimal residual disease negativity as a measure of treatment effect in multiple myeloma. This reflects a focus on deeper response evaluation alongside broader measures of disease control such as progression-free survival.
- Minimal residual disease negativity
- Progression-free survival
- Response assessment
These research interests are relevant to understanding the depth and durability of myeloma treatment responses.
Elderly Patient Care in Hematologic Oncology
Trials also address elderly patients with relapsed myeloma, highlighting the therapeutic needs of older adults in hematologic oncology. This includes attention to treatment selection in later-line disease and in patients who may require tailored approaches because of age-related considerations.
- Elderly patients
- Hematologic oncology
- Later-line myeloma treatment
The research landscape includes options intended for older individuals facing recurrent multiple myeloma.
